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Abstract: 1 
We investigated the ability of testosterone (T) to restore differentiation in multiple 2 
population doubled (PD) murine myoblasts, previously shown to have reduced 3 
differentiation in monolayer and bioengineered skeletal muscle cultures vs. their parental 4 
controls (CON) (Sharples et al. 2011, Sharples et al., 2012). Cells were exposed to low serum 5 
conditions in the presence or absence of T (100 nM) ± PI3K inhibitor (LY294002) for 72 hrs 6 
and 7 days (early and late muscle differentiation respectively). Morphological analyses were 7 
performed to determine myotube number, diameter (μm) and myonuclear accretion as 8 
indices of differentiation and myotube hypertrophy. Changes in gene expression for 9 
myogenin, mTOR and myostatin were also performed. Myotube diameter in CON and PD 10 
cells increased from 17.32 ± 2.56 μm to 21.02 ± 1.89 μm and 14.58 ± 2.66μm to 18.29 ± 11 
3.08μm (P ≤ 0.05) respectively after 72 hrs of T exposure. The increase was comparable in 12 
both PD (+25%) and CON cells (+21%) suggesting a similar intrinsic ability to respond to 13 
exogenous T administration. T treatment also significantly increased myonuclear accretion 14 
(% of myotubes expressing 5+ Nuclei) in both cell types after 7 days exposure (P ≤ 0.05). 15 
Addition of PI3K inhibitor (LY294002) in the presence of T attenuated these effects in 16 
myotube morphology (in both cell types) suggesting a role for the PI3K pathway in T 17 
stimulated hypertrophy. Finally, PD myoblasts showed reduced responsiveness to T 18 
stimulated mRNA expression of mTOR vs. CON cells and T also reduced myostatin 19 
expression in PD myoblasts only. The present study demonstrates testosterone 20 
administration improves hypertrophy in myoblasts that basally display impaired 21 
differentiation and hypertrophic capacity vs. their parental controls, the action of 22 
testosterone in this model was mediated by PI3K/Akt pathway.  23 
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1. Introduction 
Muscle wasting occurs within many life-threatening diseases such as cancer (termed cancer 
cachexia) [1], AIDS [2], Sepsis [3], heart failure [4] and ageing (sarcopenia) [5-7]. 
Individuals that experience muscle loss during these various disease states have a reduced 
physiological and functional capacity, altered metabolism [8,9] and a reduction in circulating 
levels of Growth Hormone, Insulin-like-Growth Factor-I (IGF-I) and Testosterone  [2]. 
These accumulative factors manifest themselves in increased frailty and morbidity and 
therefore reduced quality of life that subsequently leads to earlier mortality [10, 11].  In the 
instance of cancer cachexia approximately 50% of patients suffer with cachexia (muscle 
atrophy), which alone accounts for 25% of all cancer deaths [12-14]. The regulation of 
skeletal muscle mass is reliant on the balance between hypertrophy (e.g. protein 
synthesis/anabolism) and atrophy (e.g. protein breakdown/catabolism). A potential clinical 
intervention for promoting a positive net balance in the favour of protein synthesis is 
Testosterone (T) administration [15, 16]. T replacement therapy has been observed to 
increase muscle strength and mass in various clinical populations including patients with 
AIDS, COPD and sarcopenia [12, 17-20]. However a limited number of studies have 
investigated the role of T in skeletal muscle hypertrophy and atrophy [21-23] at the cellular 
level.  
Skeletal muscle fibre numbers are set in-utero i.e. fibres are terminally differentiated or post 
mitotic and unable to divide. Skeletal muscles regenerative capacity therefore occurs as a 
result of a specialised cell type, the satellite cell, which resides underneath the basal lamina 
of the mature fibre and has mitotic potential. With the relevant cues, satellite cells are 
activated (termed myoblasts), then proliferate or return to quiescence for subsequent 
regenerative bouts. Activated myoblasts repair the muscle by fusing with the existing fibres, 
a process known as differentiation [24, 25]. Most recently, our laboratories have highlighted 
two myoblast models to study reduced differentiation capacity [7, 26, 27]. The first 
investigated the parental mouse C2 myoblasts vs. their subclone, the C2C12 cells. Despite their 
shared origins, we observed differences in morphological and biochemical responses 
between the C2 and C2C12 cells. The C2 cells displayed slower and diminished differentiation 
profiles compared to the C2C12 cells and were also more susceptible to TNF-α-induced 
inhibition of differentiation and induction of apoptosis [27]. Because muscle wasting is 
associated with reduced muscle mass [28, 29] and increased susceptibility to TNF-induced 
muscle protein degradation [30-32], this comparative model provided us with an excellent 
representation of muscle atrophy, hypertrophy and adaptability, thus, enabling the 
determination of potential regulators associated with muscle wasting. The second model 
utilised C2C12 cells that had undergone multiple population doublings (PD) vs. parental 
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control cells (CON), which have undergone no doublings relative to the PD cells [7]. These 
cells also display impaired differentiation in monolayer [7] and in three dimensional culture 
systems [26] vs. their parental controls. We reported that the PD cells had a significantly 
reduced number of cells exiting the cell cycle in G1, a prerequisite for fusion, with 
corresponding decreases in transcript expression of IGF-I, myoD, myogenin and reduced 
activation of Akt with increases in IGFBP5 mRNA and JNK activation vs. control cells [7]. 
Interestingly, similar morphology, transcript and signalling processes were also observed in 
cells isolated from aged human muscle [33-35] and in whole tissue biopsies [36, 37]. Thus, 
these cells can be used as a representative model to investigate mechanisms of atrophic 
phenotypes (PD) vs. parental control cells (CON) that display hypertrophic phenotypes [7].  
In the present study we utilised the latter model to investigate T administration on 
PD cells displaying impaired differentiation. As the PD cells display a reduction in Akt 
activation [7], the PI3K/Akt/mTOR pathway was investigated in the present study, as it is 
inextricably involved in protein synthesis [38] and most recently linked to T’s regulation of 
muscle hypertrophy [23].  
The aims were to: 1) Improve the impaired differentiation and hypertrophy profiles 
observed previously in PD cells using T administration; 2) Manipulate the role of PI3K/Akt 
in Ts regulation of differentiation in PD and CON cells. We hypothesised that T would 
induce improved differentiation and hypertrophy in CON cells and would improve the 
impaired differentiation in the PD cells. Further by inhibiting PI3K, testosterone’s ability to 
restore differentiation action would be negated in both cell types. The overall objective of 
the research was to utilise an in vitro model that is representative of impaired differentiation 
(PD) in order to elucidate the ability of T to improve differentiation and hypertrophy and to 
investigate its cellular and molecular mechanisms of action. 
  
SUBMITTED VERSION ONLY- There will be errors in this manuscript version in comparison with 
the final published version available in J Steriod Biochem Mol Bol at: Link. 
5 
 
2. Materials and Methods 
2.1 Cell Culture 
Mouse C2C12 [39, 40] (ATCC, Rockville, MD, USA) skeletal muscle myoblasts were seeded at 
80,000 cells per ml in 2 ml of growth media (GM) per well (Dulbecco’s modifed eagle’s 
medium, DMEM (Sigma, Dorset, UK)), 20% fetal bovine serum (FBS) (PAA, Somerset, UK), 
1% PenStrep (Invitrogen, Paisley, UK)) onto 0.2% porcine gelatin-coated (Sigma, Dorset, 
UK) 6-well plates (Fisher Scientific, Loughborough, UK) and grown in a humidified 5% CO2 
atmosphere at 37oC. Population doubled (PD) cells and their parental controls (CON) were 
developed as detailed in Sharples et al. [7, 26]. Briefly, PD cells underwent an extra 58-60 
population doublings vs. their CON cells. Once confluent, the myoblasts were changed from 
growth media to low serum media/differentiation media (DM; composed of: DMEM, 2% 
horse serum (HS), 1% Penstrep and 1% L-Glutamine) which promotes the fusion of the 
myoblasts into multinucleated myotubes. C2C12 myoblasts undergo spontaneous 
differentiation into myotubes on serum withdrawal, and do not require growth factor 
addition to stimulate the process [40]. Cells were incubated in DM for 30 minutes at 37oC in 
a 5% CO2 atmosphere with this period of equilibration denoted as, 0 hour time point. Cells at 
the time points of 72 hrs and 7 days (early and late muscle differentiation respectively) were 
fixed (see below) for subsequent morphology analyses or isolated for reverse transcription 
quantitative real-time polymerase chain reaction (RT-PCR). 
2.2 Cell Treatments 
All treatments were administered in DM described above. The treatments comprised of a 
vehicle control (DMSO at a concentration of 0.01%), Testosterone alone (T) 100 nM (Tocris 
Bioscience, Bristol, UK), PI3K inhibitor (LY) 5 μM (LY294002- Calbiochem, Middlesex, UK), 
100 nM T + 5 μM LY. DMSO was used as the solvent for T reconstitution at the same 
concentration as the vehicle (0.01%). For results and figure legends the following 
nomenclature will be used DMSO, T, LY and T + LY respectively. All treatments were added 
at 0 hrs and existing media was further supplemented at 72 hrs. The inhibitor, LY at a dose 
of 5 μM has been extensively shown to be highly specific and effective in C2C12 cells in 
inhibiting PI3K and downstream Akt [41-46].  
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2.3 RNA Isolation 
Plates for each time point (0 hrs, 72 hrs and 7 days) were washed with 1ml/well phosphate 
buffer saline (PBS) (Fisher Scientific, Loughborough, UK) and extracted for RNA using 250 
μl TRIzolTM Reagent (Sigma, Dorset, UK) in each well. Total RNA was extracted by following 
manufacturer’s instructions. RNA concentration and purity were assessed through UV 
spectroscopy at ODs of 260 and 280 nm, using the Nanodrop spectrophotometer 3000 
(Fisher, Rosklide, Denmark). Only samples with a 260:280 ratio of between 1.9 and 2.15 
were carried forward for reverse transcription and PCR analysis detailed below.  
2.4 Primer Design 
Primer sequences (Table 1.) were identified using Gene (NCBI, www.ncbi.nlm.nih.gov/gene) 
and designed using both web-based OligoPerfect™ Designer (Invitrogen, Carlsbad, CA, USA) 
and Primer-BLAST (NCBI, http://www.ncbi.nlm.nih.gov/tools/primer-blast). Sequence 
homology searches ensured specificity. Three or more GC bases in the last 5 bases at the 3’ 
end of the primer were avoided. Secondary structure interactions (hairpins, self-dimer and 
cross dimer) within the primer were avoided. All primers ranged between 18 and 23 bp and 
amplified a product between 173 and 197 bp. GC content was between 36.3 and 55.5% (Table 
1). Primers without the requirement of further purification were purchased from Sigma 
(Suffolk, UK). 
 
<<<INSERT TABLE 1. NEAR HERE>>> 
 
2.5 Reverse Transcription Quantitative Real Time Polymerase Chain Reaction (rt-qRT-
PCR) 
70 ng of RNA/sample was reverse transcribed and amplified using QuantiFast™ SYBR® 
Green RT-PCR one-step kit on a Rotogene 3000Q (Qiagen, Crawley, UK) supported by 
Rotogene software (Hercules, CA, USA). rt-qRT-PCR was performed as follows: 10 min, 50oC 
(reverse transcription), 5 min 95oC (transcriptase inactivation and initial denaturation), 
Followed by: 10 secs, 95oC (denaturation), 30 secs, 60oC (annealing and extension) for 40 
cycles. Following completion, melting curve analyses were performed to exclude primer-
dimer and non-specific amplification (all melt analysis in this study presented single 
reproducible peaks). All PCR efficiencies were comparable (standard deviation ± 0.03%) 
across all conditions and genes. Relative mRNA expression was quantified for myogenin, 
mTOR and myostatin (Table 1.) using the comparative Ct (ΔΔct) method [7, 47] against a 
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stable reference gene of RP-IIb (combined Ct value for all runs across experimental 
conditions 16.63 ± 0.38) and calibrator of CON treatment at 0 hrs.  
2.6 Morphological Analysis 
Following media aspiration and 2 × PBS washes (1 ml/well), cells were fixed by adding 1 ml 
methanol/acetone (1:1) to 1 ml PBS in each well in a drop-wise manner and incubated for 10 
mins RT. Following aspiration, 2 ml methanol and acetone (1:1) were added to each well and 
incubated for a further 10 mins. Finally PBS (2ml/well) was added after removal of the 
methanol and acetone mix and plates were stored at 4oC until further analyses. This fixing 
process allows nuclei to become discernible under light microscopy alone, without the need 
for additional nuclear staining. A total of 30 fields per condition for each time point were 
captured with a cell imaging system at x10 magnification (Inverso-TC, CETI, Medline 
Scientific Limited, Oxon, UK) and analysed using Image J (Java) software (National 
Institutes of Health, USA). Morphology was assessed by determination of myotube diameter, 
number of myotubes per view, mean number of nuclei per myotube per field of view, fusion 
index (cell fusion) and total nuclei counts (changes in total cell number and therefore an 
indices for proliferation). A myotube was defined as containing 3+ nuclei encapsulated within 
cellular structures, so to avoid counting of single cells undergoing mitosis. Myotube diameter 
(μm) was determined by measuring the diameter of 3 equidistant points on each myotube 
(left end, middle, right end) and determining the mean of the 3 values as previously 
described [48, 49]. An indicator of myonuclear accretion (fusion index) was calculated by 
dividing myotubes into two classes; myotubes which expressed 3-4 nuclei or myotubes which 
expressed 5+ nuclei, with the data expressed as percentages.  
2.7 Statistical Analyses  
Experiments were performed 3 times (n = 3) in triplicate. Data are presented as mean + S.D. 
Morphology data at 72 hrs were assessed using a (2×2) mixed two-way factorial ANOVA 
(GraphPad Software, Inc., San Diego, USA) for interactions between cell type (PD, CON) and 
treatments (DMSO, T). LY and T+LY treatment were excluded from the aforementioned 
analysis, as there were no observable myotubes at 72 hrs in these conditions. Morphology 
data at 7 days were assessed using a (2×4) mixed two-way factorial ANOVA for interactions 
between cell type (PD, CON) and treatments (DMSO, T, LY and T + LY). Gene expression 
data were assessed using a (2×2×4) mixed three-way factorial ANOVA for interactions 
between cell type (PD, CON), time (72 hrs and 7 days) and treatments (DMSO, T, LY and T + 
LY). Bonferroni post hoc analyses were performed where main effects for treatment or cell 
type occurred, without a significant interaction between treatment and cell type. If 
significant interactions were present, independent t-tests were conducted to confirm 
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statistical significance between variables of interest. Furthermore, paired-sample t-tests were 
undertaken for variable of interests within cell type and treatment. Myonuclear Accretion 
(fusion index) measures were analysed using Chi Square to investigate whether myotube 
categories (3-4 nuclei or 5+ nuclei) differed from one another based on treatment exposure. 
A P-value of ≤ 0.05 was considered to represent a statistically significant difference.  
3. Results  
 
3.1 Exogenous T treatment increases myotube hypertrophy in both CON and PD cells  
The administration of exogenous DMSO, T, LY, T+LY to CON and PD cells brought about 
morphological changes in differentiation (Figs 1 & 2). Firstly, it is important to mention that 
in support of previous observations showing reductions in differentiation in PD vs. CON cells 
[7]; a significant difference for mean myotube diameter at 72 hrs was again observed in the 
present study (CON 17.32 ± 2.56 vs. PD 14.58 ± 2.66, P = 0.01, Fig. 3A, supporting the 
atrophic phenotype observed previously in PD cells [7,26]. Importantly, in the present study, 
T administration appeared to increase hypertrophy (myotube diameter) in both cell types. 
Statistical analyses confirmed the morphological observations in Fig. 1 and 2 and revealed 
that a T-stimulus significantly increased myotube diameter in both CON and PD cells after 
72 hrs (CON+T 21.02 ± 1.89 vs. CON 17.32 ± 2.56; PD+T 18.29 ± 3.08 vs. PD 14.58 ± 2.66, P 
= 0.01, Fig. 3A) and 7 days (CON+T 22.03 ± 2.65 vs. CON 17.50 ± 2.38; PD+T 20.49 ± 1.99 
vs. PD 15.70 ± 1.59, P = 0.01, Fig. 3A) compared with non-treated cells, respectively.  
 
<<<INSERT FIGURE NEAR HERE 1.>>> 
 
Importantly, the magnitude of change between both cell models in response to T 
administration and compared with their respective baseline controls was not significantly 
different at either time points, with T increasing myotube diameter in both PD (+25% and 
+23%) and CON (+21% and +20%) cells to the same extent after 72 hrs (Fig. 3A) and 7 days 
(Fig. 3C); respectively. Overall, this suggests that cells with a reduced differentiation 
phenotype have the same capacity to undergo hypertrophy in response to exogenous 
testosterone administration as CON cells. Furthermore, the addition of T significantly 
increased myotube number in CON cells (CON+T 2.90 ± 0.72 vs. CON 2.23 ± 0.68, P ≤ 0.05, 
Fig. 3D) after 7 days exposure only (at 72 hrs although there were mean increases this was 
not statistically significant (P = N.S.)). There were no significant changes in myotube 
number in PD cells after 72 hours or 7 days exposure (P = N.S.). This suggests testosterone 
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increases hypertrophy (myotube diameter) in both cells types; however, T only enhanced 
myotube number in CON cells at 7 days.  
 
 <<<INSERT FIGURE NEAR HERE 2.>>>  
 
Together with the changes in myotube diameter at both 72 hrs and 7 days, T significantly 
increased the mean number of nuclei per myotube in CON cells (CON 3.77 ± 0.86 vs. CON+T 
4.98 ± 1.76, P ≤ 0.001, Fig. 3B) at 72 hrs and at 7 days (CON 3.68 ± 0.67 vs. CON+T 4.91 ± 
1.10, P ≤ 0.01, Fig. 3B); again substantiating the morphological observation that 
hypertrophy, rather than hyperplasia was occurring in response to T administration. 
Furthermore, in the PD cells, a similar response was observed for nuclei/tube in the presence 
of T at 72 hrs (PD+T 4.27 ± 1.03 vs. PD 3.33 ± 0.71, P = 0.03, Fig. 3B), and 7 days (PD+T 
5.18 ± 1.31 vs. PD 3.84 ± 0.71, P ≤ 0.001 Fig. 3B) exposure compared to non-treated cells. 
Interestingly, again there were similar magnitude increases in CON and PD cells in the 
presence of T vs. basal conditions at 72 hrs (24.3% CON vs. 22% PD) and 7 days (25.1% CON 
vs. 25.9% PD). 
 
<<<INSERT FIGURE NEAR HERE 3.>>> 
 
 
3.2 PI3K/Akt inhibitor (LY) inhibits testosterone-induced increases in differentiation and 
hypertrophy for CON and PD cells  
The presence of LY inhibitor alone led to a lack of differentiation with no quantifiable 
myotubes being present in both CON and PD cells at 72 hrs (Fig. 1 & 2). As highlighted 
above; the addition of T significantly increased differentiation shown by enhanced myotube 
number in CON cells (CON+T 2.90 ± 0.72 vs. CON 2.23 ± 0.68, P ≤ 0.05, Fig. 3D) after 7 
days exposure. The presence of LY co-incubated with T significantly reduced the effect on 
myotube number (CON+T+LY 2.21 ± 0.56 vs. CON+T 2.90 ± 0.72, P ≤ 0.05, Fig. 3D). LY 
alone was also able to reduce myotube number vs. T treatment (CON+LY 1.77 ± 0.65 vs. 
CON+T 2.90 ± 0.72, P ≤ 0.05, Fig 3D) and non-treated controls (2.23 ± 0.68, P ≤ 0.01, Fig 
3D). Interestingly, T in the presence of the LY inhibitor was unable to restore differentiation, 
shown by non-significant differences with LY alone conditions (P = N.S.) and non-treated 
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CON cells (Fig. 3D). These observations highlight that Ts increase in myotube number in 
CON cells, as previously observed, is blunted in the presence of the LY inhibitor; returning 
differentiation back to basal levels. As previously highlighted there were no significant 
changes in myotube number after T administration in PD cells. However, LY alone was able 
to reduce myotube number vs. T treatment (PD+LY 1.89 ± 0.80 vs. PD+T 2.35 ± 0.69, P ≤ 
0.05, Fig 3D) and non-treated controls (PD 2.26 ± 0.53, P = 0.05, Fig 3D).  
Following these observations for indices of differentiation we next wished to ascertain the 
impact of T in the presence of the PI3K inhibitor (LY) on myotube hypertrophy. At 7 days, as 
previously highlighted above, the addition of T significantly increased myotube diameter in 
CON and PD cells (Fig. 3C). The presence of LY co-incubated with T significantly reduced the 
effect on myotube diameter in both CON (CON+T+LY 17.49 ± 2.21 vs. CON+T 22.03 ± 2.65, 
P ≤ 0.05, Fig. 3C) and PD cells (PD+T+LY 17.10 ± 2.40 vs. PD+T 20.49 ± 1.99, P ≤ 0.05, Fig. 
3C). LY alone was also able to reduce myotube diameter vs. T treatment in CON cells 
(CON+T 22.03 ± 2.65 vs. CON+LY 17.7 ± 2.91, P ≤ 0.05, Fig 3C). Similar observations were 
observed in PD cells (PD+T 20.49 ± 1.99 vs. PD+LY 15.83 ± 2.53, P ≤ 0.05, Fig 3C). 
Interestingly, T was unable to restore myotube diameter in the presence of the LY inhibitor 
shown by non-significant differences with LY alone conditions in CON cells and non-treated 
CON cells (P = N.S, Fig. 3C). The same observations were mirrored in PD cells where T was 
unable to restore myotube diameter in the presence of the LY inhibitor shown by non-
significant differences with LY alone conditions in PD cells (P = N.S, Fig. 3C). Overall, this 
shows that T’s observed increases in hypertrophy was blunted in the presence of the LY 
inhibitor returning myotube diameter back to basal levels in both cell types.  
3.3 T-treatment enhancement in differentiation and hypertrophy is accompanied by 
increases in cell fusion 
 To address the effects of the various treatments on cell fusion, myonuclear accretion 
was calculated. The administration of T resulted in a greater percentage of myotubes 
expressing 5+ nuclei for both CON (CON+T 67.9% vs. CON 32.1%, 𝝌𝟏
𝟐= 32.99, P ≤ 0.05) and 
PD cells (PD+T 67.2% vs. PD 32.8%, 𝝌𝟏
𝟐= 20.58, P ≤ 0.05) compared to untreated cells after 
7 days exposure (Fig 4A & 4B respectively). Furthermore, the addition of LY with T 
treatment reduced the percentage of myotubes expressing 5+ nuclei back to similar levels of 
LY-alone treated cells (CON+T+LY 28.1% vs. CON+LY 15.2%, 𝝌𝟏
𝟐= 2.53, P = N.S; PD+T+LY 
37.5% vs. PD+LY 21.6%, 𝝌𝟏
𝟐= 3.4, P=N.S, Fig 4A & 4B respectively). In accordance with these 
observations, there was no significant difference in total nuclei counts for all treatments in 
either cell type at both time points (P = N.S). There was however a significant interaction 
between cell type as the PD cells had a significantly higher total nuclei count (P ≤ 0.05) 
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compared to CON cells at both time points, a finding confirmed previously by Sharples et al. 
[7], who highlighted a continued proliferation at the expense of exiting the cell cycle in G1 
and differentiating.  
 
<<<INSERT FIGURE 4. NEAR HERE>>> 
 
3.4 Expression of myogenin mRNA increases after T-administration in both PD and CON 
cells 
There was a significant difference in myogenin transcript expression levels between CON 
and PD cells after 72 hrs (CON 191.51 ± 12.84 vs. PD 48.58 ± 8.14, P ≤ 0.001, Fig. 5A) and 7 
days exposure (CON 128.36 ± 27.11 vs. PD 59.22 ± 4.57, P ≤ 0.001, Fig. 5A). Whilst still 
remaining significantly different, the expression of myogenin significantly increased in both 
CON and PD cells when treated with T (CON+T 222.18 ± 36.63 vs. CON 191.51 ± 12.84; 
PD+T 67.00 ± 5.35 vs. PD 48.58 ± 8.14, P ≤ 0.05, Fig. 5A) after 72 hrs. The increase in 
myogenin mRNA expression also continued at 7 days in PD treated cells (PD + T 74.15 ± 8.13 
vs. PD 59.22 ± 4.57, P ≤ 0.001, Fig. 5A), yet there was no difference in myogenin mRNA 
expression at this time point between non-treated and T-treated CON cells. However, 
absolute levels of myogenin transcript expression were basally significantly higher (shown 
above) in CON treated cells vs. PD treated (CON+T 131.46 ± 24.53 vs. PD+T 67.00 ± 5.35, P 
= 0.001) cells at 7 days. The presence of LY, significantly reduced myogenin expression after 
72 hrs exposure in CON cells (CON+LY 134.38 ± 16.13 vs. CON 191.51 ± 16.00, P ≤ 0.05 Fig. 
5A), with no reductions being observed in PD cells at the same time point. Furthermore, LY 
alone had no effect on myogenin mRNA expression after 7 days culture in either cell type (P 
= N.S Fig. 5A). 
 
<<<INSERT FIGURE NEAR HERE 5.>>> 
 
T in the presence of LY inhibitor significantly attenuated myogenin expression after 72 hrs 
when compared with T alone in both cell types (CON+T 222.18 ± 36.63 vs. CON+T+ LY 
146.09 ± 24.58, P ≤ 0.05; PD+T 67.00 ± 5.35 vs. PD+T+LY 56.04 ± 11.50, P ≤ 0.05, Fig. 5A). 
At 7 days, there were no significant changes for any treatment conditions in CON cells (P = 
N.S for all comparisons) for myogenin expression. However in PD cells, T further enhanced 
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myogenin expression significantly, even when administered in the presence of LY (PD 59.22 
± 4.57 vs. PD+T+LY 69.93 ± 3.98, P ≤ 0.05; PD+LY 57.04 ± 9.22 vs. PD+T+LY 69.93 ± 3.98, 
P ≤ 0.05 Fig. 5A). Thus, T caused an increase in myogenin expression in both cells types, 
whether LY was present or absent. This may suggest at the molecular level at least, that T 
elevates myogenin expression, independently of PI3K/Akt, but appears to be not sufficient 
enough to rescue morphological differentiation/hypertrophy in PD cells.  
3.5 Testosterone increases mTOR expression in the presence of PI3K inhibitor in CON cells   
The expression of mTOR did not change after 72 hrs in either cell type (CON 0.97 ± 0.08 vs. 
PD 0.97 ± 0.12, Fig. 5B). After 7 days exposure, T administration alone significantly 
increased mTOR mRNA expression compared to CON non-treated cells (CON+T 121.08 ± 
15.87 vs. CON 111.95 ± 19.36, P ≤ 0.05 Fig. 5B). Furthermore, the treatment of T + LY 
significantly increased mTOR mRNA compared to LY alone (CON+T +LY 135.14 ± 16.08 vs. 
CON+LY 112.70 ± 13.62, P ≤ 0.001, Fig. 5B) and untreated controls (CON+T +LY 135.14 ± 
16.08 vs. CON 111.95 ± 19.36, P ≤ 0.05). This highlights T administration increases in mTOR 
expression even in the presence of LY. In the PD cells, all treatments were without effect on 
mTOR expression at 7 days exposure (Fig. 5B).   However, at 7 days under basal conditions, 
CON cells displayed significantly higher mTOR expression than PD cells (CON 111.95 ± 19.36 
vs. PD 1.01 ± 0.10, P ≤ 0.05, Fig. 5B). 
3.6 T-stimulus reduces negative muscle mass regulator myostatin in PD cells only  
Myostatin transcript expression was slightly elevated in PD cells after 72 hrs compared to 
CON, although these elevations were not statistically significant (CON 5.93 ± 1.87 vs. PD 
7.63 ± 2.58, Fig. 5C). However, at 7 days, statistically significant observations were observed 
for increases in myostatin mRNA expression in PD cells compared to CON cells (PD 12.93 ± 
4.69 vs. CON 4.57 ± 1.20, P ≤ 0.001 Fig. 5C). This novel finding suggests that under basal 
conditions, myostatin may block differentiation in these myoblasts and thus contribute 
towards reduced myotube hypertrophy. In CON cells, T treatments, LY alone or co-
incubations of T+LY at 72 hrs did not alter myostatin mRNA expression (Fig. 5C). The 
presence of LY alone was the only treatment to significantly reduce myostatin mRNA 
expression after 72 hrs exposure to PD cells (PD+LY 4.27 ± 2.47 vs. PD 7.63 ± 2.58, P ≤ 0.01 
Fig. 5C).  
At 7 days, there were no changes in myostatin mRNA expression in CON cells (CON 4.57 ± 
1.20; CON+T 5.99 ± 1.40; CON+LY 4.32 ± 1.65; CON+T+LY 4.84 ± 1.01, Fig. 5C). However 
in the PD cells, T treatment significantly impaired elevations in myostatin expression 
compared to PD non-treated cells (PD + T 9.73 ± 2.56 vs. PD 12.93 ± 4.69, P ≤ 0.05 Fig. 5C). 
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The reduction in myostatin transcript expression was significantly larger in magnitude with 
the addition of T with LY (-36%) in PD cells at the 7 day time point (PD + T + LY 3.47 ± 0.83 
vs. PD 12.93 ± 4.69, P ≤ 0.01 Fig. 5C), yet similar effects were not observed in CON cells. 
However, the presence of LY alone also brought about reductions in myostatin expression 
(PD+LY 4.98 ± 2.25 vs. PD 12.93 ± 4.69, P ≤ 0.001 Fig. 5C) and the reductions were similar 
to T+LY (P = N.S). Overall, suggesting both LY and testosterone alone reduce myostatin 
expression in PD cells only. It therefore appears that T potentially reduces myostatin 
expression in atrophied PD cells only suggesting a potential mechanism that may explain the 
increase in differentiation/hypertrophy seen in this cell type, whereas in CON cells, the 
increases with T are independent of myostatin expression.   
4. Discussion 
The present study supports a role for testosterone  in enhancing myogenic 
differentiation and myotube hypertrophy [50-55] but more importantly, shows the capacity 
to improve hypertrophy and myonuclear accretion in a previously established model 
displaying impaired differentiation and hypertrophy similar to that of atrophic phenotypes 
such as ageing [7, 26]. Furthermore, testosterone treatment enhanced hypertrophy shown by 
increases in myotube diameter, nuclei per myotube and a larger number of myotubes with 5 
or more nuclei in both control (CON) and multiple population doubling (PD) cells. 
Interestingly, testosterone improved hypertrophy (myotube diameter) to the same 
magnitude in both cell types at 72 hrs and 7 day time points. Thus, despite PD cells having 
undergone multiple population doublings vs. their controls, and therefore displaying a 
reduced basal differentiation capacity as previously described in Sharples et al. [7, 26]; 
testosterone was able to exert similar magnitude increases in myotube hypertrophy. Despite 
this interesting observation, testosterone was unable to fully restore differentiation (myotube 
number) to the level observed in untreated control cells at 7 days; perhaps suggesting 
testosterones predominant role in hypertrophy rather than differentiation in this model. 
Furthermore, in line with previous findings, the current study showed that PD cells had 
reduced myogenin expression vs. CON cells [7, 26], with the present study also supporting 
previous morphological and biochemical (reduced CK activity) findings [7, 26], showing 
myotube diameter was reduced in the PD cells. This further consolidates the use of these 
cells as a representative model to investigate cellular and molecular mechanisms of atrophic 
(PD) vs. hypertrophic phenotypes (CON). 
Importantly, testosterone mediated increases in myotube hypertrophy were 
potentiated via the PI3K/Akt pathway, where inhibition of this pathway in the presence of 
testosterone rendered the hormone unable to exert its potent influence on myotube 
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hypertrophy in both cell types. This study supports previous work where the PI3K/Akt 
pathway has been implicated in testosterones action in L6 myoblasts [22] and human 
skeletal myoblasts [56] where the same PI3K inhibitor (LY294002) also reduced 
testosterone induced hypertrophy. Kovacheva and colleagues [57] have also previously 
reported that Akt signalling downstream of PI3K was restored by testosterone 
administration in elderly mice. The present study further supports that testosterones action 
in myotube hypertrophy is mediated via PI3K/Akt pathway, especially where reductions in 
Akt activation have been previously reported in this model (i.e. lower in PD vs. CON) [7]. 
Overall, these observations further suggest that the manipulation of this pathway by 
testosterone may be imperative for therapeutic restoration of muscle atrophy [38].  
Interestingly, exogenous testosterone improved myogenin expression in both CON 
and PD cells types, whether the PI3K inhibitor (LY294002) was present or absent, 
suggesting testosterone-mediated activation of myogenin independently of the PI3K/Akt 
signalling pathway. Testosterone has previously been shown to increase myogenin in C2C12 
cells [50, 51]. Indeed, community-dwelling older men treated with grades doses of 
testosterone show increases in muscle fibre size accompanied by increased myogenin 
expression [55]. Despite this, testosterone induced increases in myogenin observed in the 
presence of PI3K inhibitor were unable to restore the differentiation/hypertrophy impinged 
by the PI3K inhibitor alone. Therefore, suggesting that myogenin was not the main 
mechanism of action in testosterone-induced increases in hypertrophy. Overall however, 
absolute levels of myogenin were severely reduced in PD vs. CON cells with testosterone 
unable to rescue absolute myogenin expression levels in the cells that display atrophic 
phenotypes (PD’s) to those observed in untreated control cells. Thus, perhaps highlighting 
myogenins more pertinent role in differentiation (not hypertrophy) as testosterone was 
unable to restore absolute levels of myogenin and corresponding myotube numbers in PD 
cells vs. untreated control levels. Although, as discussed above, testosterone was able to 
improve myotube diameter i.e. hypertrophy.  
In addition to this, testosterone increased mTOR expression in CON cells at 7 days, 
previously testosterone has been shown to increase mTOR phosphorylation in both L6 rat 
[22] and in C2C12 [23] myoblasts. Indeed, mTOR mRNA expression in CON cells was 
increased in the presence of testosterone plus PI3K inhibitor (LY), perhaps suggesting an 
important role for testosterone in increasing mTOR independently of PI3K/Akt. 
Furthermore, White and colleagues [23] also observed increases in mTOR phosphorylation 
with incremental doses of T in C2C12 cells, independently of Akt activation. However, mTOR 
expression was not increased in PD cells in the presence of testosterone alone or in 
combination with the PI3K inhibitor suggesting impaired mTOR transcript expression in 
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response to exogenous testosterone in the atrophic, reduced differentiation phenotype PD vs. 
control cells. Previously, in our labs we have observed reduced IGF-I transcript expression 
with corresponding reductions in Akt phosphorylation in PD myoblasts [7]. As Akt is 
upstream of mTOR this suggests Akt may be involved the reduction of mTOR observed 
between CON and PD myoblasts basally at 7 days. However, activity of mTOR was not 
directly assessed in the present study and warrants further investigation.  
 
In agreement with the present study where mTOR expression in CON cells was 
increased in the presence of testosterone plus PI3K inhibitor (LY) (albeit mRNA expression 
and not protein activity), other studies have shown that mTOR activation can occur via 
signals independent of canonical IGF-I/Akt, via a pathway involving phospholipase D, 
phosphatidic acid and a downstream regulator Rheb (ras homologue enriched brain) [58-
61]. Redd 2 may also be important in inhibiting mTOR via the tuberous sclerosis 1 (TSC1) 
and 2 (TSC2) complex [62]. As mTOR mRNA expression is increased in CON vs. PD cells, 
testosterone increases mTOR expression in CON cells which is blunted in PD cells at 7 days, 
and mTOR transcript expression is still increased with testosterone even the presence of 
PI3K/Akt inhibitor it begs the question as to the role of testosterone in regulating 
phospholipase D, phosphatidic acid, Rheb and Redd2 and their subsequent interaction with 
mTOR. Especially in light of recent data where following mechanical overload Redd2 is 
reduced to enable mTOR to initiate p70S6K activity, which is involved in protein synthesis 
and hypertrophy, a process that is impaired in the elderly [63]. 
 
Myostatin is a negative regulator of muscle mass in many species [64-67]. There is 
evidence indicating that myostatin inhibits satellite cell activation, proliferation, and 
differentiation [55, 68, 69], possibly mediated through perturbation of Akt and mTOR 
signalling [49]. Therefore reductions in myostatin, as previously observed with testosterone 
administration [69], can enhance muscle mass regulation in muscle wasting diseases such as 
cachexia and sarcopenia [70-72]. Interestingly, in the current study myostatin mRNA 
expression was reduced in myoblasts that have basally impaired hypertrophy (PD cells) 
when administered with testosterone with corresponding increases in myotube hypertrophy. 
The reduction in myostatin mRNA expression at 7 days with T treatment was accompanied 
by increases in myogenin mRNA expression in PD cells, which is supported recent literature 
highlighting myostatin’s role for inhibiting myogenic differentiation [49, 73, 74]. Despite 
this, testosterone did not return absolute levels of myostatin expression to the low levels 
observed in the control cells. These observations suggest that although testosterone may 
reduce myostatin expression, it is not entirely responsible for the improved hypertrophy 
observed in the atrophic phenotype cells. Furthermore, the PI3K inhibitor (LY) alone also 
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substantially reduced myostatin expression where there is a distinct lack of differentiation 
and hypertrophy. This is in contrast to recent studies where there was a reduction in the 
activity of Akt observed in the presence of exogenous myostatin in human myoblasts [49]. 
Therefore, if myostatin was reduced, PI3K/Akt activity may be expected to increase. 
Although inhibition of PI3K in the present study makes it difficult to compare with the 
aforementioned study, this phenomenon requires further investigation in the current model.  
It is important to note the potential effect of T breakdown which may occur within 
the cell culture media as the steroidgenic enzymes 5-α reductase and aromatase are critical 
in converting T to dihydrotestosterone (DHT) and estradiol respectively [75, 76]. Therefore, 
knowing if T is the active steroid compound stimulating hypertrophy in the current model is 
a limiting factor. Future studies may address the impact of other steroid hormones such as 
DHT in rescuing impaired differentiation and hypertrophy via the PI3K/Akt pathway. 
5. Conclusion 
In the present study exogenous testosterone was able to increase hypertrophy in myoblasts 
with reduced differentiation potential (PD cells) to a similar magnitude as the control cells. 
Testosterone induced myotube hypertrophy was mediated via the PI3K/Akt pathway, where 
inhibition of this pathway in the presence of testosterone rendered the hormone unable to 
exhibit its potent influence on myotube hypertrophy in phenotypically atrophic (PD) and 
hypertrophic control (CON) cells Testosterone-induced hypertrophy was also accompanied 
by increased myonuclear accretionin both cell types, with corresponding increases in 
myogenin expression. Furthermore, blunted mTOR expression was observed in response to 
exogenous testosterone administration in atrophic myotubes (PD) vs. control (CON) 
myotubes. Myostatin expression was reduced in the presence of testosterone in atrophic cells 
only. Overall, administration of testosterone shows strong potential to enhance hypertrophy 
in a previously atrophic cell type via the PI3K/Akt pathway.  
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Table 1. Primer sequences for genes of interest. 
Gene Primer Sequence (5’-3’) Ref. Sequence Number Amplicon Length (bp) GC% Content 
Myostatin F: 
TACTCCGAATAGAAGCCATAA 
R: GTAGCGTGATAACGTCATC 
NM_010834 194 36.3 
45 
mTOR F: 
CACTCCACTATCCTGTTACCT 
R: GAGATCCTTGGCACACCT 
 NM_020009  190 47.6 
55.5 
Myogenin F:CCAACTGAGATTGTCTGTC 
R: GGTGTTAGCCTTATGTGAAT 
NM_031189 173 47.3 
40 
RP-IIβ F:GGTCAGAAGGGAACTTGTGG
TAT 
R:GCATCATTAAATGGAGTAGC
GTC 
NM_153798.1 197 50 
44.4 
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Figure 1. 
 
 
Fig. 1. Representative light microscope images (10× magnification) of treatments (DMSO, T, LY, T + LY) exposed to the CON cell type after 72 h and 7 
days. 
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Figure 2.  
 
Fig. 2. Representative light microscope images (10× magnification) of treatments (DMSO, T, LY, T + LY) to population doubled cells after 72 h and 7 days. 
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Figure 3. 
 
Fig. 3. The effect of T-stimulus on CON and PD cells on various morphology variables after 
72 h and 7 days exposure. (A) The effect of T-stimulus on mean myotube diameter for CON 
and PD cells after 72 h exposure. *Reduced mean myotube diameter between CON and PD 
cells (P≤0.01). **T-stimulus significantly increased mean myotube diameter in CON cells vs. 
non-treated CON and PD (P ≤0.01). Dash line represents magnitude change in mean 
myotube diameter with T-stimulus, similar in magnitude for both CON (+21%) and PD 
(+25%) cells. A similar pattern was observed at 7 days (CON +20%; PD +23%). (B) The 
changes in mean nuclei per myotube at 72 h and 7 days with and without exogenous T 
administration. *T significantly increased mean nuclei per myotube in CON (+24%; P ≤ 
0.001) cells after 72 h and 7 days (+25%; P≤0.001) exposure vs. non-treated cells. **T-
treatment in PD cells increased mean nuclei per myotube after 72 h (+22%; P = 0.033) and 7 
days exposure (+25%; P≤0.001). (C) Myotube number is attenuated when LY is co-incubated 
with T at 7 days. *The presence of LY significantly reduced the effect of T on myotube 
diameter (P ≤ 0.05) in CON cells. **A similar effect was observed in PD cells (P ≤ 0.05). / = 
Myotube diameter significantly reduced in PD vs. CON cells, similar to that observed at 72 h 
(see Fig. 2A) (P ≤ 0.05). Dash line represents magnitude change in mean myotube diameter 
with T-stimulus, similar in both CON (+20%) and PD (+23%) cells. It appears that T’s action 
on myotube hypertrophy requires the activity of the PI3K/Akt pathway in both cell types. (D) 
The effect of T and LY treatment on myotube number in CON and PD cells at 7 days. *T-
treated CON cells significantly exhibited a greater number of myotubes compared to non-
treated cells (P≤0.05). **The addition of LY alone and in the presence of T significantly 
reduced the number of myotubes compared to T-treated CON cells (P≤0.05). ***In PD cells, 
LY alone significantly reduced myotube number (P≤0.01) at 7 days, with all other treatments 
showed no significant effects.  
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Figure 4.  
 
Fig. 4. The effect of T and LY treatment on myonuclear accretion in CON (A) and PD (B) 
cells after 7 days exposure. T-treatment significantly increased the percentage of myotubes 
expressing 5+ nuclei in both cell types (P ≤ 0.05). LY alone reduced the percentage of 5+ 
nucleated myotubes back to baseline levels in both cell types. T in the presence of PI3K 
inhibitor (LY) was unable to to restore the number of 5+ nucleated myotubes to the levels 
induced by T alone. 
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Figure 5.  
 
Fig. 5. The effect of T-stimulus on mRNA expression of myogenin (A), mTOR (B) and 
myostatin (C) in CON and PD cells. (A) The effect of T-stimulus on myogenin mRNA 
expression levels after 72 h exposure. *T-stimulus significantly increased myogenin 
expression in CON and PD cells compared to non-treated cells (P ≤ 0.05). **The presence of 
LY with T treatment significantly attenuated T’s effect in CON cells (P ≤ 0.05). ***T exposure 
continued to increase myogenin mRNA in PD cells after 7 days culture, even in the presence 
of LY (P ≤ 0.05). B) Changes in mTOR mRNA expression with the various treatments to 
CON and PD cells after 7 days culture. *CON + T and **CON + T + LY significantly increased 
mTOR expression vs. CON untreated cells (P ≤ 0.05). ***There was a significant difference 
in mTOR expression between CON + LY and CON + T + LY (P ≤ 0.001). Additionally there 
was a significant difference in mTOR expression between untreated CON and PD cells in 7 
days culture. There were no changes in PD cells with the same treatments at either time 
points. (C) The effect of T-stimulus on myostatin mRNA expression after 7 days exposure. *T 
significantly reduced myostatin expression in the PD treated cells after 7 days (P ≤ 0.01). 
**LY alone significantly reduced myostatin levels (P ≤ 0.01) at 72 h and 7 days. / = Plus with 
the addition of T to LY, this reduction was heightened (P ≤ 0.01) compared to non-treated 
PD cells._Basal PD cells had significantly elevated myostatin mRNA levels at 7 days vs. 
parental controls (P ≤ 0.001). 
